Stockscreener 앱 받기
7.69
5.41%
-0.44
시간 외 거래:
7.68
-0.01
-0.13%
전일 마감가:
$8.13
열려 있는:
$8.2
하루 거래량:
84,987
Relative Volume:
0.73
시가총액:
$40.87M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-0.3167
EPS:
-24.2853
순현금흐름:
$-85.33M
1주 성능:
+3.08%
1개월 성능:
-6.67%
6개월 성능:
-72.07%
1년 성능:
-43.57%
1일 변동 폭
$7.54
$8.49
1주일 범위
$7.09
$8.49
52주 변동 폭
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.69 | 49.16M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Why Aligos Therapeutics Inc. stock attracts strong analyst attentionFree Fast Exit and Entry Strategy Guide - Newser
Does Aligos Therapeutics Inc. show high probability of reboundSupport and Resistance Zone Summary Chart - Newser
News impact scoring models applied to Aligos Therapeutics Inc.Proven Trading System with Consistent Gains - Newser
Ranking Aligos Therapeutics Inc. among high performing stocks via toolsReal-Time Investment Signal Forecast with AI - Newser
What indicators show strength in Aligos Therapeutics Inc.Free AI Powered High Return Stock Calls - Newser
Custom watchlist performance reports with Aligos Therapeutics Inc.Free Entry Alert Based on Volume Spikes - Newser
Can Aligos Therapeutics Inc. rally from current levelsSummary of Reliable Long-Term Trade Models - Newser
What's behind ALGS' volatile quarterly earnings? - AInvest
Will Aligos Therapeutics Inc. stock go up soonExpert-Backed High Yield Stock Watchlist - Newser
Will Aligos Therapeutics Inc. price bounce be sustainableTrend Reversal Watch with Entry Signals - Newser
Is Aligos Therapeutics Inc. showing signs of accumulationConsistent Gain Plan with AI Support - Newser
How Efficient Is Aligos Therapeutics Inc. at Controlling Operating CostsTrend Reversal Watch with Entry Signals - Newser
Is it too late to sell Aligos Therapeutics Inc.Technical Setup Guide for Daily Watchlist - Newser
Volatility clustering patterns for Aligos Therapeutics Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionLong-Term Stock Growth Forecast Insights - Newser
Aligos Therapeutics Reports Q2 EPS of $1.53, Misses Consensus - AInvest
Aligos 2025 Q2 Earnings Sharp Loss as Net Income Plummets 413% - AInvest
Aligos Therapeutics Reports Q2 2025 Progress and Results - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54) - TipRanks
Aligos Therapeutics Reports Second Quarter 2025 Financial Results and Progress on Clinical Studies - Quiver Quantitative
Aligos Reports Breakthrough HBV Drug Results: 100% Patient Response in Phase 1 as Pivotal Trial Launches - Stock Titan
Best data tools to analyze Aligos Therapeutics Inc. stockSecure Asset Flow and Trend Pattern Analysis - Newser
How Aligos Therapeutics Inc. stock performs during market volatilitySwing Trade Planning with Consistent Setup - Newser
Real time breakdown of Aligos Therapeutics Inc. stock performanceShort Squeeze Opportunities with Indicators - Newser
Moving Average Trends for Aligos Therapeutics Inc. Stock: What They IndicateRisk-Managed Swing Setup and Signal Analysis - Newser
Is Aligos Therapeutics Inc. a good long term investmentUnlock real-time stock alerts for quick profits - Jammu Links News
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Analyzing drawdowns of Aligos Therapeutics Inc. with statistical toolsFree Long Hold Safe Return Strategy - Newser
What are analysts’ price targets for Aligos Therapeutics Inc. in the next 12 monthsExceptional trading results - Jammu Links News
What makes Aligos Therapeutics Inc. stock price move sharplyConsistently high returns - Jammu Links News
Is it the right time to buy Aligos Therapeutics Inc. stockExceptional profit potential - Jammu Links News
What are the technical indicators suggesting about Aligos Therapeutics Inc.Rapid market gains - Jammu Links News
How many analysts rate Aligos Therapeutics Inc. as a “Buy”Exceptional stock performance - Jammu Links News
How strong is Aligos Therapeutics Inc. company’s balance sheetExplosive trading opportunities - Jammu Links News
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):